Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
NCT ID: NCT06417502
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20000 participants
OBSERVATIONAL
2022-04-29
2031-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
NCT07049172
Construction of a Multi-center Clinical Research Collaboration Network for Children with Congenital Heart Disease in China
NCT06885307
Observation and Treatment of Pulmonary Microthrombosis in Childhood Pneumonia With Elevated D-dimer
NCT04778917
Prediction of Renal Parenchymal Damage of CAKUT
NCT04537364
A Integrated Study in Pediatric Patients with Cardiomyopathy
NCT06641830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hospital-based databases are established and standardized with Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for routine data collection. A web-based registry website is established with standardized electronic case report forms to register patients from CAPRID centers. A mobile application is created to allow long-term follow up and patient-reported outcome collection. The data captured in this registry reflects a "real world" situation with no intervention done outside the routine clinical practice. Treatment plans are determined by the investigator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity)
* Diagnosed and Treated in China
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospital of Chongqing Medical University
OTHER
Central South University
OTHER
Beijing Children's Hospital
OTHER
Shenzhen Children's Hospital
OTHER_GOV
Children's Hospital of Nanjing Medical University
OTHER
The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)
UNKNOWN
Zhejiang University
OTHER
Third Hospital of Peking University
UNKNOWN
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hongmei Song
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongmei Song, MD
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Third Hospital of Peking University
Beijing, Beijing Municipality, China
Chidren's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Shenzhen Children's Hospital
Shenzhen, Guangdong, China
The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)
Shenzhen, Guangdong, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Children's Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Huawei Mao, MD, PhD
Role: primary
Zhiqiang Yan, PhD
Role: primary
Xuemei Tang, MD
Role: primary
Jun Yang, MD
Role: primary
Wanling Yang, PhD
Role: primary
Xiaochuan Wu, MD
Role: primary
Haiguo Yu, MD
Role: primary
Meiping Lu, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
The Official Website for Chinese Alliance of Pediatric Rheumatic \& Immunologic Diseases (CAPRID)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021YFC2702000
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
JS-3362D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.